Combining suramin and a chimeric toxin directed to basic fibroblast growth factor receptors increases therapeutic efficacy against human melanoma in an animal model

Cancer

Volumn 86, Issue 9, 1999, Pages 1733-1741

  Davol, Pamela A ^a   Garza, Scott ^a   Frackelton Jr , A Raymond ^a,b  

^a BROWN UNIVERSITY   (United States)

^b ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

Basic fibroblast growth factor; Chimeric proteins; Drug resistance; Fibroblast growth factor receptors; Melanoma; Recombinant fusion proteins; Saporin; Severe combined immunodeficient mice; Suramin; Xenografts

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BASIC FIBROBLAST GROWTH FACTOR; BASIC FIBROBLAST GROWTH FACTOR SAPORIN; CHIMERIC PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR; SAPORIN; SURAMIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG MIXTURE; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; FIBROBLAST GROWTH FACTOR 2; HUMANS; MALE; MELANOMA; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PLANT PROTEINS; RECOMBINANT FUSION PROTEINS; SURAMIN; TIME FACTORS;

EID: 0033231038     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991101)86:9<1733::AID-CNCR15>3.0.CO;2-H     Document Type: Article

References (46)

1. Balch CM, Reintgen DS, Kirkwood JM, Houghton A, Peters L, Ang KK. Cutaneous melanoma. In: DeVita VT Jr., Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott-Raven Publishers, 1997: 1947-94.
2. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitmen S, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-97.
3. Cole BF, Gelber RD, Kirkwood JM, Goldhirsch A, Barylak E, Borden E. Quality-of-life-adjusted survival analysis of interferon alpha-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1996;14:2666-73.
4. Bear HD, Hamad GG, Kostuchenko PJ. Biologic therapy of melanoma with cytokines and lymphocytes. Semin Surg Oncol 1996;12:436-45.
5. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86: 1159-66.
6. Denijn M, Ruiter DJ. The possible role of angiogenesis in the metastatic potential of human melanoma. Melanoma Res 1993;3:5-14.
7. Herlyn M, Shih IM. Interactions of melanocytes and melanoma cells with the microenvironment. Pigment Cell Res 1994;7:81-8.
8. Reed JA, McNutt NS, Albino AP. Differential expression of basic fibroblast growth factor (bFGF) in melanocyte lesions demonstrated by in situ hybridization. Implications for tumor progression. Am J Pathol 1994;144:329-36.
9. Aviezer D, Hecht D, Safran M, Eiseinger M, David G, Yayon A. Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth-factor-receptor binding, mitogenesis, and angiogenesis. Cell 1994;79:1005-13.
10. La Rocca RV, Stein CA, Myers CE. Suramin: prototype of a new generation of antitumor compounds. Cancer Cells 1990; 2:106-15.
11. Parker B, Swain SM, Zugmaier G, DeLap RL, Lippman M, Wellstein A. Detectable inhibition of heparin-binding growth factor activity in sera from patients treated with pentosan polysulfate. J Natl Cancer Inst 1993;85: 1068-73.
12. Nakamura S, Sakurada S, Salahuddin SZ, Osada Y, Tanaka NG, Sakamoto N, et al. Inhibition of development of Kaposi's sarcoma-related lesions by a bacterial cell wall complex. Science 1992;255:1437-40.
13. Eckhardt SG, Burris HA, Eckardt JR, Weiss G, Rinaldi D, Barrington R, et al. Phase I assessment of novel angiogenesis inhibitor DS4152. Proc AASCO 1994;13:A23.
14. Hawking F. Suramin: with special reference to onchoserciasis. Adv Pharmacol Chemother 1978;15:289-322.
15. Hosang M. Suramin binds to platelet-derived growth factor and inhibits its biological activity. J Cell Biochem 1985;29: 265-73.
16. Myers C, Cooper M, Stein C, LaRocca R, Walther MM, Weiss G, et al. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 1992;10:881-9.
17. Eisenberger MA, Reyno LM, Jodrell DI, Sinibaldi VJ, Tkaczuk KH, Sridhara R, et al. Suramin, an active drug for prostate cancer: interim observations in a Phase I trial. J Natl Cancer Inst 1993;85:611-21.
18. Taylor CW, Lui R, Fanta P, Salmon SE. Effects of suramin on in vitro growth of fresh human tumors. J Natl Cancer Inst 1992:84:489-94.
19. Zabrenetzky VS, Kohn EC, Roberts DD. Suramin inhibits laminin- and thrombospondin-mediated melanoma cell adhesion and migration and binding of these adhesive proteins to sulfatide. Cancer Res 1990;50:5937-42.
20. Nakajima M, DeChavigny A, Johnson CE, Hamada J, Stein CA, Nicolson GL. Suramin. A potent inhibitor of melanoma heparanase and invasion. J Biol Chem 1991;266:9661-6.
21. LaRocca RV, Cooper MR, Uhrich M, Danesi R, Walther MM, Linehan WM, et al. Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation. Urol Clin N Am 1991;18:123-9.
22. Horne MK, Wilson OJ, Cooper M, Gralnick HR, Myers CE. The effect of suramin on laboratory tests of coagulation. Thromb Haemost 1992;67:434-9.
23. O'Donnell BP, Dawson NA, Weiss RB, Myers CE, James WD. Suramin-induced skin reactions. Arch Dermatol 1992;128: 75-9.
24. Thibault A, Figg WD, Cooper MR, Prindiville SA, Sartor AO, Headlee DJ, et al. Anaphalactoid reaction with suramin. Pharmacotherapy 1993;13:656-7.
25. Figg WD, Cooper MR, Thibault A, Headlee DJ, Humphrey J, Bergan RC, et al. Acute renal toxicity associated with suramin in the treatment of prostate cancer. Cancer 1994; 74:1612-4.
26. Davol PA, Frackelton AR Jr., Calabresi P. Growth factor-toxin chimeras and their applications. In: McKay IA, Brown KD, editors. Growth factors and receptors: a practical approach. Oxford: Oxford University Press, 1998:199-225.
27. Sosnowski BA, Gonzalez AM, Chandler LA, Buechler YJ, Pierce GF, Baird A. Targeting DNA to cells with basic fibroblast growth factor (FGF2). J Biol Chem 1996;271:33647-53.
28. Goldman CK, Rogers BE, Douglas JT, Sosnowski BA, Ying W, Siegal GP, et al. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res 1997;57:1447-51.
29. Beitz JG, Davol P, Clark J, Kato J, Medina M, Frackelton AR Jr., et al. Antitumor activity of basic fibroblast growth factor-saporin mitotoxin in vitro and in vivo. Cancer Res 1992;52: 227-30.
30. Davol P, Beitz JG, Frackelton AR Jr. Autocrine down-regulation of basic fibroblast growth factor receptors causes mitotoxin resistance in a human melanoma cell line. J Invest Dermatol 1995;104:916-21.
31. Davol P, Beitz JG, Mohler M, Ying W, Cook J, Lappi DA, et al. Saporin toxins directed to basic fibroblast growth factor receptors effectively target human ovarian teratocarcinoma in an animal model. Cancer 1995;76:79-85.
32. Davol P, Frackelton AR Jr. The mitotoxin, basic fibroblast growth factor-saporin, effectively targets human prostatic carcinoma in an animal model. J Urol 1996;156:1174-9.
33. Ying W, Martineau D, Beitz J, Lappi DA, Baird A. Anti-B16-F10 melanoma activity of basic fibroblast growth factor saporin mitotoxin in vitro and in vivo. Cancer 1994;74:848-53.
34. Siegall CB, Gawlak SL, Chace DF, Merwin JR, Pastan I. In vivo activities of acidic fibroblast growth factor-Pseudomonas exotoxin fusion protein. Bioconj Chem 1994;5:77-83.
35. Gawlak SL, Pastan I, Siegall CB. Basic FGF-Pseudomonas exotoxin chimeric proteins: comparison with acidic FGF-Pseudomonas exotoxin. Bioconj Chem 1993;4:483-9.
36. Endo Y, Mitsui K, Motizuki M, Tsurugi K. The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. J Biol Chem 1987;262:5908-12.
37. Lappi DA, Ying W, Barthelemy I, Martineau D, Prieto I, Benatti L, et al. Expression and activities of a recombinant basic fibroblast growth factor-saporin fusion protein. J Biol Chem 1994;269:12552-8.
38. Lappi DA, Maher PA, Martineau D, Baird A. The basic fibroblast growth factor-saporin mitotoxin acts through the basic fibroblast growth factor receptor. J Cell Physiol 1991;147:17-26.
39. Roberts BJ, Hook KE, Whitfield LR, Elliott WL, Dykes DJ, Carter CA, et al. Lack of efficacy of suramin against orthotopically implanted LNCaP and PC-3 prostate tumor xenografts at clinically relevant blood levels. Proc AACR 1995;36: 1613A.
40. Stein CA, LaRocca RV, Thomas R, McAtee N, Myers CE. Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 1989;7:499-508.
41. Dawson N, Figg WD, Brawley OW, Bergan R, Cooper MR, Senderowicz DH, et al. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal. Clin Cancer Res 1998;4:37-44.
42. Ying W, Martineau D, Frautschy S, Lappi DA, Baird A. The pharmacokinetics of basic FGF-saporin in the normal rat. Proc AACR 1994;35:2560A.
43. Blakey DC, Skilleter DN, Price RJ, Watson GJ, Hart LI, Newell DR. Comparison of the pharmacokinetics and hepatotoxic effects of saporin and ricin A-chain immunotoxins on murine liver parenchymal cells. Cancer Res 1988;48:7072-8.
44. Bojanowski K, Lelievre S, Markovits J, Couprie J, Jacquemin-Sablon A, Larsen AK. Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Proc Natl Acad Sci USA 1992;89:3025-9.
45. Ghosh J, Miller RA. Suramin an experimental chemotherapeutic drug irreversibly blocks T cell CD45-protein tyrosine phosphatase in vitro. Biochem Biophys Res Commun 1993; 194:36-44.
46. Panagiotidis G, Salehi AA, Lundquist I. Effect of the lysosomotropic drug suramin on islet lysosomal enzyme activities and the insulin-secretory response induced by various secretagogues. Pharmacology 1991;43:163-8.